Posted on 21/04/2009 in Pharmacy Supplier News GlaxoSmithKline's (GSK's) drug alli will give adults a "real opportunity" to lose weight, it has claimed.
It is the first non-prescription product for weight loss that has been approved by the European Commission (EC) and is now available in pharmacies across the continent.
When combined with a lower calorie and reduced fat diet, alli has shown in clinical trials to help individuals shed 50 per cent more body mass compared to if they only altered what they ate.
Taken with food, the recommended dose of one 60 mg capsule three times a day is intended for use in adults with a BMI of 28 kg/m2 or more.
Manfred Scheske is the president of GSK's European consumer healthcare division.
He remarked: "[The drug] has been well received by millions of people in the US and we are very excited about the number of people it could help across Europe achieve their goal to lose weight."
Last month, the EC also authorised the company's paediatric pneumococcal vaccine ? Synflorix - to protect against diseases such as meningitis. Other news stories from 21/04/2009
Read more in the Zenopa News Archive
How this news is generated
|
